Grant: Fellowship - Priority Announcement: Gastroenterology
University of Alberta
$63,875.00
GSK3B inhibitors prevent HCV release through purturbation of VLDL assembly
EF 2014-15
Résumé
Hepatitis C virus (HCV) treatment has progressed in the past few years with better response rates. Although there has been considerable work in the field, there are still many unanswered questions and many untreated patients. Besides the detrimental liver cirrhosis and hepatocellular carcinoma (HCC) occurring late during the disease, HCV infection can also be associated with liver steatosis and insulin resistance. This increases the disease morbidity and mortality and has been linked to disturbances in glycogen synthase kinase 3 (GSK3B) signaling. Moreover, there is evidence that HCV hijacks the secretory pathway of very low density lipids (VLDL) for its release from hepatic cells. We found that inhibition of GSK3B in Huh7.5 cells leads to an intracellular accumulation of viral proteins with a parallel decrease in the amount of infectious virions secreted into the cell culture media. Based on the possible role of the VLDL secretory pathway in HCV release, we hypothesized that down-regulation of GSK3B inhibits HCV release through perturbing the VLDL secretory pathway with subsequent trapping of the virus in the cells. Our plan is to investigate the role of GSK3B inhibitors on HCV assembly and release from Huh7.5 cells and the possible mechanisms implicated. Next, we will examine modulators of the VLDL assembly pathway that could be impaired by GSK3B inhibition such as lipoproteins ApoB100, ApoE and microsomal transfer protein (MTP). We expect a change in the lipid profile that impedes the virus release from the cells.
Programme
Fellowship - Priority Announcement: Gastroenterology
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
319724
Name
Sarhan Mohammed A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
GSK3B inhibitors prevent HCV release through purturbation of VLDL assembly
Programtype2
Fellowship Programs
Orgnameinp2
University of Alberta
Cihramount2
$63,875
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Gastroenterology
Keyworddelim
Dna Microarray; Flow Cytometry; Immunohistochemistry; Immunology And Immunopathology; Molecular Biology; Protein Microarray; Statistics; Tissue Cultures; Virology; Western Blotting
Abstract
Hepatitis C virus (HCV) treatment has progressed in the past few years with better response rates. Although there has been considerable work in the field, there are still many unanswered questions and many untreated patients. Besides the detrimental liver cirrhosis and hepatocellular carcinoma (HCC) occurring late during the disease, HCV infection can also be associated with liver steatosis and insulin resistance. This increases the disease morbidity and mortality and has been linked to disturbances in glycogen synthase kinase 3 (GSK3B) signaling. Moreover, there is evidence that HCV hijacks the secretory pathway of very low density lipids (VLDL) for its release from hepatic cells. We found that inhibition of GSK3B in Huh7.5 cells leads to an intracellular accumulation of viral proteins with a parallel decrease in the amount of infectious virions secreted into the cell culture media. Based on the possible role of the VLDL secretory pathway in HCV release, we hypothesized that down-regulation of GSK3B inhibits HCV release through perturbing the VLDL secretory pathway with subsequent trapping of the virus in the cells. Our plan is to investigate the role of GSK3B inhibitors on HCV assembly and release from Huh7.5 cells and the possible mechanisms implicated. Next, we will examine modulators of the VLDL assembly pathway that could be impaired by GSK3B inhibition such as lipoproteins ApoB100, ApoE and microsomal transfer protein (MTP). We expect a change in the lipid profile that impedes the virus release from the cells.
Competitiondate
201411
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Sarhan, Mohammed A
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $63,875~ $0~